Status of immune mediators in painful neuropathies

Michaelis M, Vogel C, Blenk KH, et al.: Inflammatory mediators sensitize acutely axotomized nerve fibers to mechanical stimulation in the rat. J Neurosci 1998, 18:7581–7587.

Üçeyler N, Sommer C: Cytokine regulation in animal models of neuropathic pain and in human diseases. Neurosci Lett 2008 (in press).

Thacker MA, Clark AK, Marchand F, McMahon SB: Pathophysiology of peripheral neuropathic pain: immune cells and molecules. Anesth Analg 2007, 3:838–847.

Kleinschnitz C, Brinkhoff J, Zelenka M, et al.: The extent of cytokine induction in peripheral nerve lesions depends on the mode of injury and NMDA receptor signaling. J Neuroimmunol 2004, 1–2:77–83.

Taskinen HS, Olsson T, Bucht A, et al.: Peripheral nerve injury induces endoneurial expression of IFN-gamma, IL-10 and TNF-alpha mRNA. J Neuroimmunol 2000, 1:17–25.

Zelenka M, Schäfers M, Sommer C: Intraneural injection of interleukin-1beta and tumor necrosis factor-alpha into rat sciatic nerve at physiological doses induces signs of neuropathic pain. Pain 2005, 3:257–263.

Junger H, Sorkin LS: Nociceptive and inflammatory effects of subcutaneous TNFalpha. Pain 2000, 1–2:145–151.

Milligan ED, Langer SJ, Sloane EM, et al.: Controlling pathological pain by adenovirally driven spinal production of the anti-inflammatory cytokine, interleukin-10. Eur J Neurosci 2005, 8:2136–2148.

Wagner R, Janjigian M, Myers RR: Anti-inflammatory interleukin-10 therapy in CCI neuropathy decreases thermal hyperalgesia, macrophage recruitment, and endoneurial TNF-alpha expression. Pain 1998, 1:35–42.

Exley AR, Smith N, Winer JB: Tumour necrosis factor-alpha and other cytokines in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1994, 9:1118–1120.

Maimone D, Annunziata P, Simone IL, et al.: Interleukin-6 levels in the cerebrospinal fluid and serum of patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neuroimmunol 1993, 1:55–61.

Kuntzer T, Radziwill AJ, Lettry-Trouillat R, et al.: Interferon-beta1a in chronic inflammatory demyelinating polyneuropathy. Neurology 1999, 6:1364–1365.

Misawa S, Kuwabara S, Mori M, et al.: Serum levels of tumor necrosis factor-alpha in chronic inflammatory demyelinating polyneuropathy. Neurology 2001, 5:666–669.

Empl M, Renaud S, Erne B, et al.: TNF-alpha expression in painful and nonpainful neuropathies. Neurology 2001, 10:1371–1377.

Mathey EK, Pollard JD, Armati PJ: TNF alpha, IFN gamma and IL-2 mRNA expression in CIDP sural nerve biopsies. J Neurol Sci 1999, 1:47–52.

Oka N, Akiguchi I, Kawasaki T, et al.: Tumor necrosis factor-alpha in peripheral nerve lesions. Acta Neuropathol 1998, 95:57–62.

Putzu GA, Figarella-Branger D, Bouvier-Labit C, et al.: Immunohistochemical localization of cytokines, C5b-9 and ICAM-1 in peripheral nerve of Guillain-Barre syndrome. J Neurol Sci 2000, 1:16–21.

Michalowska-Wender G, Adamcewicz G, Wender M: Impact of cytokines on the pathomechanism of diabetic and alcoholic neuropathies. Folia Neuropathol 2007, 2:78–81.

Teles RM, Antunes SL, Jardim MR, et al.: Expression of metalloproteinases (MMP-2, MMP-9, and TACE) and TNF-alpha in the nerves of leprosy patients. J Peripher Nerv Syst 2007, 3:195–204.

Zhang J, Dong H, Li B, et al.: Association of tumor necrosis factor polymorphisms with Guillain-Barre syndrome. Eur Neurol 2007, 1:21–25.

Singer OC, Otto B, Steinmetz H, Ziemann U: Acute neuropathy with multiple conduction blocks after TNFalpha monoclonal antibody therapy. Neurology 2004, 9:1754.

Richez C, Blanco P, Lagueny A, et al.: Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. Neurology 2005, 8:1468–1470.

Wallace DJ, Margolin K, Waller P: Fibromyalgia and interleukin-2 therapy for malignancy. Ann Intern Med 1988, 6:909.

Watkins LR, Maier SF, Goehler LE: Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses and pathological pain states. Pain 1995, 3:289–302.

Barnes PF, Chatterjee D, Brennan PJ, et al.: Tumor necrosis factor production in patients with leprosy. Infect Immun 1992, 4:1441–1446.

Gür A, Karakoç M, Erdogan S, et al.: Regional cerebral blood flow and cytokines in young females with fibromyalgia. Clin Exp Rheumatol 2002, 6:753–760.

Üçeyler N, Valenza R, Stock M, et al.: Reduced levels of antiinflammatory cytokines in patients with chronic widespread pain. Arthritis Rheum 2006, 8:2656–2664.

Huygen FJ, De Bruijn AG, De Bruin MT, et al.: Evidence for local inflammation in complex regional pain syndrome type 1. Mediators Inflamm 2002, 1:47–51.

Üçeyler N, Eberle T, Rolke R, et al.: Differential expression patterns of cytokines in complex regional pain syndrome. Pain 2007, 1–2:195–205.

Brisby H, Olmarker K, Larsson K, et al.: Proinflammatory cytokines in cerebrospinal fluid and serum in patients with disc herniation and sciatica. Eur Spine J 2002, 1:62–66.

Burke JG, Watson RW, McCormack D, et al.: Spontaneous production of monocyte chemoattractant protein-1 and interleukin-8 by the human lumbar intervertebral disc. Spine 2002, 13:1402–1407.

Kotani N, Kudo R, Sakurai Y, et al.: Cerebrospinal fluid interleukin 8 concentrations and the subsequent development of postherpetic neuralgia. Am J Med 2004, 5:318–324.

Bernateck M, Rolke R, Birklein F, et al.: Successful intravenous regional block with low-dose tumor necrosis factor-alpha antibody infliximab for treatment of complex regional pain syndrome 1. Anesth Analg 2007, 4:1148–1151, table of contents.

Huygen FJ, Niehof S, Zijlstra FJ, et al.: Successful treatment of CRPS 1 with anti-TNF. J Pain Symptom Manage 2004, 2:101–103.

Lindenlaub T, Sommer C: Cytokines in sural nerve biopsies from inflammatory and non-inflammatory neuropathies. Acta Neuropathol 2003, 6:593–602.

Backonja MM, Coe CL, Muller DA, Schell K: Altered cytokine levels in the blood and cerebrospinal fluid of chronic pain patients. J Neuroimmunol 2008 Mar 4 (Epub ahead of print).

Ludwig J, Binder A, Schattschneider J, et al.: Cytokine expression in serum and cerebro-spinal fluid of patients with polyneuropathy. Der Schmerz 2007, 21(Suppl):109.

Üçeyler N, Rogausch JP, Toyka KV, Sommer C: Differential expression of cytokines in painful and painless neuropathies. Neurology 2007, 69:42–49.

Hoitsma E, Faber CG, van Santen-Hoeufft M, et al.: Improvement of small fiber neuropathy in a sarcoidosis patient after treatment with infliximab. Sarcoidosis Vasc Diffuse Lung Dis 2006, 23:73–77.

Üçeyler N, Kafke W, Toyka KV, Sommer C: Local and systemic cytokine expression in patients with small fiber neuropathy [abstract]. J Peripher Nerv Syst 2007, 12(Suppl 1):87.

Wesseldijk F, Huygen FJ, Heijmans-Antonissen C, et al.: Tumor necrosis factor-alpha and interleukin-6 are not correlated with the characteristics of complex regional pain syndrome type 1 in 66 patients. Eur J Pain 2007 Dec 3 (Epub ahead of print).

Alexander GM, van Rijn MA, van Hilten JJ, et al.: Changes in cerebrospinal fluid levels of pro-inflammatory cytokines in CRPS. Pain 2005, 3:213–219.

Alexander GM, Perreault MJ, Reichenberger ER, Schwartzman RJ: Changes in immune and glial markers in the CSF of patients with complex regional pain syndrome. Brain Behav Immun 2007, 5:668–676.

Schwartzman RJ, Chevlen E, Bengtson K: Thalidomide has activity in treating complex regional pain syndrome. Arch Intern Med 2003, 12:1487–1488; author reply 1488.

Manning DC: Immunomodulatory agents for neuropathic pain syndromes: from animals to CRPS and beyond. Eur J Pain 2006, 10(Suppl 1):S20.